Leukotriene b4 derivatives, in particular oximo-ltb4 antagonists
CA 2291123 A1 · Owner: Jaroch, Stefan · Inventors: Giesen, Claudia; Buchmann, Bernd; Frohlich, Wolfgang
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to leukotriene B4 derivatives of general formula (I) in which R1 stands for H, CF3, CH2OH; R2 stands for an organic acid radical; R3 stands for H, C1-C14-alkyl, C3-C10-cycloalkyl or a 5-6-link aromatic , heterocyclic ring with at least one heteroatom; R4 is hydrogen C1-C10-alkyl, C3-C10-cycloalkyl; A is a transtrans-CH=CH-CH=CH, a -CH2CH2-CH=CH- or a tetramethylene group; B is a C1-C10 linear or branched-chain aklylene group or the group (a) or (b); D is a direct bonding oxygen, sulphur, -CC-, -CH=CR7, or a direct bonding with B; R5 and R6 are identical or different and are H or C1-C4-alkyl, or R6 stands for H and R5 stands for C1-C15-alkanoyl or R8 SO2-; R7 is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 22, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 22, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 22, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.